A practical reference on LC-MS/MS: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-04-27. Anything still debated is marked as such rather than presented as settled.
Detection in biological samples can be complicated by rapid metabolism and low circulating concentrations. Some studies report phase I and phase II metabolites, and analytical methods may need to target those species in addition to the parent compound. Immunoassays are not broadly available, so mass spectrometry remains the main confirmatory approach. For anti-doping testing, laboratories look for SR9009 and its metabolites using validated LC-MS methods. Open questions include how long metabolites remain detectable and how different routes of administration alter detection windows.
In laboratory settings, SR9009 is typically characterized by liquid chromatography–mass spectrometry (LC-MS) or high-performance liquid chromatography with ultraviolet detection (HPLC-UV). These methods can confirm identity and estimate purity, but they require reference standards for accurate quantification. Because SR9009 is not a licensed pharmaceutical, no harmonized pharmacopeial monograph exists. Laboratories often validate in-house methods for matrices such as plasma, urine, or cell culture media. Sample preparation may involve protein precipitation or liquid-liquid extraction before analysis.
Because REV-ERB receptors are core clock components, SR9009 has been examined for effects on daily rhythms as well as metabolism. Research has explored whether the compound can shift or reinforce circadian gene expression in tissues such as liver and muscle. Some studies report improved metabolic markers in obese or diabetic mice, while others show context-dependent responses. Questions remain about which effects are direct, which are secondary to timing, and how they might differ across species.
SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.
SR9009 binds REV-ERB receptors and alters their repressive activity on target genes. This action can change transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. In rodent studies, treated animals have shown changes in muscle oxidative capacity and exercise performance, though effects vary by dose, duration, and model. The precise molecular steps connecting receptor binding to whole-body outcomes are still an active area of investigation. Findings in animals do not automatically translate to humans.
| Property | Value | Notes |
|---|---|---|
| Appearance | Off-white to pale yellow solid | Visual description varies with purity and source |
| Solubility | Soluble in DMSO and ethanol; poorly soluble in water | Organic stock solutions are common in research |
| Typical storage | -20 °C, desiccated, protected from light | Avoid repeated freeze-thaw cycles |
| Typical analytical method | LC-MS or HPLC-UV | Reference standards are needed for quantification |
| Molar mass | Approximately 437.9 g/mol | Calculated from the reported free-base formula |
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
SR9009 stability depends on temperature, moisture, light, and solvent. Solid material is generally kept cool and dry, while solutions may require protection from repeated warming and cooling. Degradation can appear as color changes, precipitate, or new chromatographic peaks. Researchers should follow supplier instructions and their own stability data. Long-term storage conditions for human use have not been established because the compound lacks approved clinical formulation.
SR9009 is supplied as a solid research chemical, often in milligram quantities. Laboratories typically weigh it in a controlled environment because fine powders can disperse. Stock solutions are commonly prepared in dimethyl sulfoxide and stored in small aliquots to reduce freeze-thaw cycles. Personal protective equipment and chemical fume hoods are standard when handling unknown or potent compounds. These practices address laboratory safety rather than human use.
Identity and purity of SR9009 samples are usually checked with chromatographic and spectrometric methods. High-performance liquid chromatography can separate the compound from related impurities, while mass spectrometry provides molecular mass confirmation. Nuclear magnetic resonance spectroscopy may be used for structural verification in research settings. No single method proves biological activity, and certificates of analysis should be reviewed alongside raw data. Independent testing is often needed because online products vary widely.
Several misconceptions surround SR9009. It is often described as a SARM, a steroid, or an exercise pill, but its known target is the REV-ERB receptor family. Rodent studies have examined exercise capacity and metabolic markers, yet human outcomes remain unproven. Oral bioavailability appears low in animals, and human pharmacokinetics are not well characterized. Online products may contain impurities or different compounds, so identity and purity testing are important for research use.
Analytical chemists detect SR9009 with liquid chromatography-tandem mass spectrometry, commonly abbreviated LC-MS/MS. Sample preparation may involve protein precipitation, liquid-liquid extraction, or solid-phase extraction before analysis. Laboratories can target the parent compound or its metabolites, depending on the matrix and the purpose of testing. Anti-doping methods require sensitive and specific assays because concentrations in biological samples can be low. Reference standards and validated methods are essential for reliable identification and quantification.
Regulatory agencies have not approved SR9009 for human therapeutic use. It is typically sold as a research chemical with labels stating that it is not for human consumption. The World Anti-Doping Agency prohibits the substance in sport, generally under the category of non-approved substances. Customs and national laws may restrict importation, sale, or possession. Product quality and legal status can vary by country and vendor, and therapeutic claims are not permitted in regulated advertising because the compound lacks approval.
Site-specific recombination makes use of phage integrases instead of restriction enzymes, eliminating the need for having restriction sites in the DNA fragments. Instead, integrases make use of unique attachment (att) sites, and catalyse DNA rearrangement between the target fragment and the destination vector. The Invitrogen Gateway cloning system was invented in the late 1990s and uses two proprietary enzyme mixtures, BP clonase and LR clonase. The BP clonase mix catalyses the recombination between attB and attP sites, generating hybrid attL and attR sites, while the LR clonase mix catalyse the recombination of attL and attR sites to give attB and attP sites. As each enzyme mix recognises only specific att sites, recombination is highly specific and the fragments can be assembled in the desired sequence. Vector design and assembly Because Gateway cloning is a proprietary technology, all Gateway reactions must be carried out with the Gateway kit that is provided by the manufacturer. The reaction can be summarised into two steps. The first step involves assembling the entry clones containing the DNA fragment of interest, while the second step involves inserting this fragment of interest into the destination clone.
24496Cm + 126C → 256102No* → 252102No + 4 10n Meanwhile, in Dubna, experiments were carried out in 1958 and 1960 aiming to synthesize element 102 as well. The first 1958 experiment bombarded 239Pu and 241Pu with 16O ions. Some alpha decays with energies just over 8.5 MeV were observed, and they were assigned to 251,252,253No, although the team wrote that formation of isotopes from lead or bismuth impurities (which would not produce nobelium) could not be ruled out. While later 1958 experiments noted that new isotopes could be produced from mercury, thallium, lead, or bismuth impurities, the scientists still stood by their conclusion that element 102 could be produced from this reaction, mentioning a half-life of under 30 seconds and a decay energy of (8.8 ± 0.5) MeV. Later 1960 experiments proved that these were background effects. 1967 experiments also lowered the decay energy to (8.6 ± 0.4) MeV, but both values are too high to possibly match those of 253No or 254No. The Dubna team later stated in 1970 and again in 1987 that these results were not conclusive. In 1961, Berkeley scientists claimed the discovery of lawrencium in the reaction of californium with boron and carbon ions. They claimed the production of the isotope 257Lr, and also claimed to have synthesized an alpha-decaying isotope of element 102 that had a half-life of 15 s and alpha decay energy 8.2 MeV. They assigned this to 255No without giving a reason for the assignment.
Food and beverage products containing cannabidiol were widely marketed in the United States as early as 2017. Hemp seed ingredients which do not naturally contain THC or CBD (but which may be contaminated with trace amounts on the outside during harvesting) were declared by the US Food and Drug Administration as generally recognized as safe (GRAS) in December 2018. CBD itself has not been declared GRAS, and under US federal law is illegal to sell as a food, dietary supplement, or animal feed. State laws vary considerably as non-medical cannabis and derived products have been legalized in various jurisdictions. Despite once having a promising market, the industry for CBD stalled out during the COVID-19 pandemic beginning in 2020, and, by 2024, it collapsed due to withdrawal of investors, the absence of a FDA ruling on efficacy and safety, inconsistent state-by-state legislation, and consumer ambivalence. Similar to energy drinks and protein bars which may contain vitamin or herbal additives, food and beverage items can be infused with CBD as an alternative means of ingesting the substance. In the United States, numerous products are marketed as containing CBD, but in reality contain little or none. Some companies marketing CBD-infused food products with claims that are similar to the effects of prescription drugs have received warning letters from the FDA for making unsubstantiated health claims. In February 2019, the New York City Department of Health announced plans to fine restaurants that sell food or drinks containing CBD, beginning in October 2019.
== Early life and education == Vasquez was born on August 3, 1984, in El Paso, Texas. He was raised in the El Paso–Juárez–Las Cruces border region, spending much of his childhood in both the United States and Mexico. He grew up in Ciudad Juárez, Mexico, where he spent time in his grandfather's television repair shop. His grandfather Javier Bañuelos, originally from Zacatecas, Mexico, had transitioned from farming to working as a mailman before establishing his repair business. Vasquez later attended Montwood High School in El Paso and then enrolled at New Mexico State University (NMSU) in Las Cruces, where he earned a Bachelor of Arts degree in English and journalism in 2008. During college, he served as the news editor and later as editor-in-chief of The Round Up, NMSU's student-run newspaper.
Column C is the original assignment by Corey and Pauling. Column K is that of Koltun's patent. Column J is the color scheme used by the molecular visualizer Jmol. Column R is the scheme used by Rasmol; when two colors are shown, the second one is valid for versions 2.7.3 and later. Column P consists of the colors in the PubChem database managed by the United States National Institute of Health. All colors are approximate and may depend on the display hardware and viewing conditions.
Sources: en.wikipedia.org
Russian: музга, muzga "pool, puddle" Lithuanian: mazgoti and Latvian: mazgāt "to wash" Sanskrit: májjati "to drown" Latin: mergō "to dip, immerse" Prekmurje Slovene: müzga "marsh, swamp" In many Slavic countries, Moskov is a surname, most commonly in Russia, Bulgaria, Ukraine, and North Macedonia. In addition, similarly named places exist in Poland, such as Mozgawa. According to a Finno-Ugric hypothesis, the Merya and Muroma people—who were among the pre-Slavic tribes that inhabited the area—called the river Mustajoki ("Black River"), and the name of the river derives from this term. Other theories, having little or no scientific basis, are rejected by linguists. The Old Russian form of the city's name has been reconstructed as *Москы, *Mosky; hence the name was one of a few Slavic ū-stem nouns. As with other nouns of that declension, the name had been undergoing a morphological transformation during an early stage of the language's development; as a result, the first written references in the 12th century were to Московь, Moskovĭ (accusative case), Москви, Moskvi (locative case), and Москвe/Москвѣ, Moskve/Moskvě (genitive case). From the latter forms came the modern Russian form Москва, Moskva, which is a result of morphological generalization with numerous Slavic ā-stem nouns. The form Moskovĭ has left traces in other languages, including the following:
==== Moxibustion and cupping ==== Four adverse events associated with moxibustion were bruising, burns and cellulitis, spinal epidural abscess, and large superficial basal cell carcinoma. Ten adverse events were associated with cupping. The minor ones were keloid scarring, burns, and bullae; the serious ones were acquired hemophilia A, stroke following cupping on the back and neck, factitious panniculitis, reversible cardiac hypertrophy, and iron deficiency anemia.
Although the ancient Egyptians did not always distinguish frankincense from other resins such as myrrh, references to incense from the land of Punt have been dated to the third millennium BCE. Incense trees being transported for cultivation in Thebes are depicted in the so-called "Punt Colonnade" at the mortuary temple of Hatshepsut. The Ebers Papyrus, from around 1500 BCE, provides some of the earliest evidence for frankincense used with intent as a possible therapy. The incense offering occupied a prominent position in the sacrificial legislation of the ancient Hebrews. The Book of Exodus (30:34–38) prescribes frankincense, blended with equal amounts of three aromatic spices, to be ground and burnt in the sacred altar before the Ark of the Covenant in the wilderness Tabernacle, where it was meant to be a holy offering—not to be enjoyed for its fragrance. The Book of Jeremiah (6:20) relates that frankincense was imported from Sheba during the 6th century BC Babylonian captivity. Frankincense is mentioned in the New Testament as one of the three gifts (with gold and myrrh) that the magi "from the East" presented to the Christ Child (Matthew 2:11).
Humanin is a micropeptide encoded in the mitochondrial genome by the 16S ribosomal RNA gene, MT-RNR2. Its structure contains a three-turn α-helix, and no symmetry. In in vitro and animal models, it appears to have cytoprotective effects.
LSD can induce physical effects such as pupil dilation, decreased appetite, increased sweating, and wakefulness. The physical reactions to LSD vary greatly, and some may be a result of its psychological effects. Commonly observed symptoms include increased body temperature, blood sugar, and heart rate, as well as goose bumps, jaw clenching, dry mouth, and hyperreflexia. In cases of adverse reactions, users may experience numbness, weakness, nausea, and tremors.
Sources: en.wikipedia.org
=== Cardiac magnetic resonance imaging === Cardiac magnetic resonance (CMR) is capable of measuring the thickness of different areas of the heart. This can be used for quantification of the deposits in the heart. CMR also shows the characterization of myocardial tissue through patterns of gadolinium enhancements. However, none of the CMR technique is able to differentiate ATTR-CM and AL-CM definitely. For AL-CM, 68% of them have symmetrical and concentric left ventricular hypertrophy. On the other hand, for ATTR-CM, 79% of them have asymmetrical left ventricular hypertrophy and 18% of them have symmetrical and concentric left ventricular hypertrophy. In T1-weighted imaging, edema in the heart can be detected with a high T1 signal. Meanwhile, enlargement of heart cells will reduce the T1 signal. Using T1 signal, Extracellular volume (ECV) is useful to determine the degree of amyloid deposition around the heart cells and detect the regression of amyloid deposits after treatment. ECV is higher in ATTR-CM than in AL-CM. In T2-weighted imaging, the T2 signal is increased in acute myocarditis (inflammation of heart muscles), and myocardial infarction (heart attack). T2 signal is also increased in AL-CM and ATTR-CM but the signal is greater in AL-CM before starting chemotherapy. Late gadolinum enhancement (LGE) can determine the severity of deposition of amyloid in heart tissue. The higher the LGE signal, the more severe the heart involvement. It can be divided into three stages: no LGE, subendocardial LGE, and full-thickness (transmural) LGE.
Dizziness Fatigue Low blood pressure Diarrhea Weakness Slowed heart rate Weight gain Erectile dysfunction Carvedilol is not recommended for people with uncontrolled bronchospastic disease (e.g. current asthma symptoms) as it can block receptors that assist in opening the airways. Carvedilol may mask symptoms of low blood sugar, resulting in hypoglycemia unawareness. This is termed beta blocker induced hypoglycemia unawareness.
Health in the United States EPODE International Network, the world's largest obesity-prevention network Fat acceptance movement Hunger in the United States List of countries by Body Mass Index (BMI) Obesogen World Fit, a program of the United States Olympic Committee Epidemiology of obesity
== Plate production == TLC plates are usually commercially available, with standard particle size ranges to improve reproducibility. They are prepared by mixing the adsorbent, such as silica gel, with a small amount of inert binder like calcium sulfate (gypsum) and water. This mixture is spread as a thick slurry on an unreactive carrier sheet, usually glass, thick aluminum foil, or plastic. The resultant plate is dried and activated by heating in an oven for thirty minutes at 110 °C. The thickness of the absorbent layer is typically around 0.1–0.25 mm for analytical purposes and around 0.5–2.0 mm for preparative TLC. Other adsorbent coatings include aluminium oxide (alumina), or cellulose.
An X-ray room must be shielded on all sides with 1 mm lead equivalent shielding. Calcium silicate or solid brick masonry is recommended. A steel jamb should be used, not only because of the weight of the heavy shielding door but also because of the shielding; wooden frames must be shielded separately. The shielding door must be covered with a 1 mm thick lead foil and a lead glass window must be installed as a visual connection. A keyhole shall be avoided. All installations (sanitary or electrical), that interrupt the radiation protection, must be leaded ( § 20 § 20 Röntgenverordnung (röv_1987) [§ 20 X-ray Ordinance] (in German) and § Annex+2 Annex 2 (to § 8 para. 1 sentence 1 RöV) (röv_1987) (in German) Depending on the application, nuclear medicine requires even more extensive protective measures, up to and including concrete walls several meters thick. In addition, from December 31, 2018, when the latest amendments to Section 14 (1) No. 2b of the Radiation Protection Act § 14 Strahlenschutzgesetz – StrlSchG [Radiation Protection Act (StrlSchG)] (in German) come into force, an expert in medical physics for X-ray diagnostics and therapy must be consulted for the optimization and quality assurance of the application and for advice on radiation protection issues.
Sources: en.wikipedia.org
It is usually detected by LC-MS or HPLC-UV against a reference standard. In biological matrices, metabolite targeting can improve detection. No universal immunoassay is widely available.
The compound is generally handled as light-sensitive and stored cold and dry. Stability in solution depends on solvent, concentration, and storage time. Specific degradation rates are not fully standardized.
Limited water solubility affects formulation for cell and animal studies. Organic co-solvents are often used to dissolve it. Precipitation can confound assay results if not controlled.
SR9009 is a synthetic research compound that acts on REV-ERB nuclear receptors. It is not approved for human use and is sold only as a research chemical. Its effects have been studied mainly in cells and rodents.